Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colifagina
- Development stage
- Phase 4
- Lead developer
- Sant’Orsola-Malpighi University Hospital
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Colifagina is an oral enterovaccine consisting of a polybacterial lysate of eight lysed bacterial strains. Classified as a biologic immunostimulant, it acts by stimulating IgA-mediated mucosal immune defenses within the gastrointestinal tract. It has been investigated for various gastrointestinal conditions, including acute gastroenteritis in children, functional bloating, and recurrent diverticulitis. In clinical studies, it has been evaluated as an adjunct to standard rehydration therapy to reduce the duration and severity of diarrheal episodes, particularly those associated with viral pathogens like astrovirus, rotavirus, and adenovirus.
- Brand names
- Colifagina
- Other names
- polybacterial lysateoral enterovaccine
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on Colifagina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Colifagina.